tldrdaily.news logo
Tag

Sigilon Therapeutics

All articles tagged with #sigilon therapeutics

finance2 years ago

"Moderna Investor's Massive 3,000% Profit from Small Biotech Investment"

Noubar Afeyan, the billionaire backer of Moderna Inc., is set to make a significant gain on another biotech investment as Sigilon Therapeutics Inc., in which his venture capital firm owns a stake, saw its value quintuple after Eli Lilly agreed to acquire the company. Afeyan's firm could potentially receive a windfall of $101 million if Sigilon meets certain benchmarks, including regulatory approval of a specified product. While the hurdles are high, investors are optimistic as the stock's closing price exceeded Lilly's initial payment. Afeyan, who holds more than 100 patents and has been involved in building over 70 startups, has become a billionaire through his investments in the life sciences industry.

via Yahoo Finance|
#billionaire#biotech#eli-lilly
business2 years ago

Sigilon Therapeutics Rockets After Acquisition by Eli Lilly

Eli Lilly has announced its acquisition of Sigilon Therapeutics, its partner in diabetes treatment, causing Sigilon's biotech stock to surge by 438.2%. The deal values Sigilon stock at $14.92 per share, with a contingent value right worth up to an additional $111.64 per share in cash tied to clinical and regulatory milestones. The total value of the deal amounts to $309.6 million. The collaboration between Lilly and Sigilon aims to develop innovative islet cell therapy solutions for type 1 diabetes, and Sigilon is also working on treatments for lysosomal and liver diseases.

via Investor's Business Daily|
#biotech-stock#business#cell-therapy
finance2 years ago

Eli Lilly's Acquisition of Sigilon Therapeutics Sends Shares Soaring

Sigilon Therapeutics shares are surging after Eli Lilly And Co announced its acquisition of the company for $14.92 per share in cash, with the potential for additional cash consideration. The transaction, expected to close in Q3 2023, comes after a collaboration between the two companies to develop encapsulated cell therapies for type 1 diabetes. Sigilon's near-term focus is on the development of SIG-002, its product candidate for type 1 diabetes, in collaboration with Eli Lilly.

via Yahoo Finance|
#acquisition#cash#development-efforts
healthcare2 years ago

Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments

Pharmaceutical company Eli Lilly has announced its plans to acquire the remaining shares of Sigilon Therapeutics, a company specializing in experimental cell therapies for diabetes patients. The deal, valued at $34.6 million in upfront cash, will provide Lilly with access to Sigilon's proprietary cell therapy candidate for treating type 1 diabetes. The acquisition is expected to close in the third quarter of 2023.

via Reuters|
#acquisition#cell-therapies#diabetes-treatments
healthcare2 years ago

Eli Lilly's Acquisition of Sigilon Therapeutics Boosts Diabetes Treatment Portfolio

Eli Lilly and Co announced its plans to acquire the remaining shares of Sigilon Therapeutics to expand its diabetes treatments. The deal, valued at $34.6 million in upfront cash, will give Lilly access to Sigilon's proprietary cell therapy candidate for type 1 diabetes. Sigilon shareholders may receive an additional $111.64 per share based on certain milestones. The acquisition is expected to close in Q3 2023.

via Yahoo Finance|
#acquisition#cell-therapies#diabetes-treatments
business2 years ago

Lilly's Acquisition of Sigilon Therapeutics Sends Shares Soaring

Eli Lilly and Company has announced its acquisition of Sigilon Therapeutics, a biopharmaceutical company focused on developing functional cures for acute and chronic diseases. The acquisition will enhance Lilly's efforts in developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The deal involves a tender offer of $14.92 per share in cash, with a potential total consideration of up to $126.56 per share. The transaction is expected to close in the third quarter of 2023.

via PR Newswire|
#acquisition#biopharmaceutical#business